BREAKINGVIEWS-Danaher’s $10 bln M&A pivot demands faith

Masimo Corporation -0.04%
Danaher Corporation +1.40%

Masimo Corporation

MASI

178.39

-0.04%

Danaher Corporation

DHR

198.61

+1.40%

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

By Robert Cyran

NEW YORK, Feb 17 (Reuters Breakingviews) - A post-Covid slump challenged the serial acquirer’s playbook of buying profitable biological product makers. A Masimo deal changes focus to patient monitoring. The switch and the seller’s odd history explain adverse investor reactions. Opportunism doesn’t imply lack of targets.

Full view will be published shortly.

Follow Robert Cyran on Bluesky.

CONTEXT NEWS

Danaher said on February 17 that it had agreed to buy Masimo, a company that makes patient monitoring systems, in a $9.9 billion deal including debt. Danaher will pay $180 for each share of Masimo, a premium of 38% to their closing price on February 13, the last day of trading before the deal was announced.

Citigroup served as financial advisor to Danaher, with Goldman Sachs providing advisory support. Centerview Partners served as advisor to Masimo, with Morgan Stanley also providing advice.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.